Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer

Open Access

Peer-reviewed

Research Article

Jianzhong Lin,

Affiliation Department of Urology, BenQ Medical Center, Nanjing Medical University, Nanjing, China
⨯
Hongfei Wu,

Affiliation Department of Urology, BenQ Medical Center, Nanjing Medical University, Nanjing, China
⨯
Hui Shi,

Affiliation Laboratory of Reproductive Health, Jiangsu Institute of Planned Parenthood Research, Nanjing, China
⨯
Wei Pan,

Affiliation Department of Oncology, the Second Hospital of Nanjing Jiangning, Nanjing, China
⨯
Hongbo Yu,

Affiliation Department of Urology, BenQ Medical Center, Nanjing Medical University, Nanjing, China
⨯
Jiageng Zhu

*E-mail: zhujiageng1972@hotmail.com

Affiliation Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
⨯

Reader Comments (0)

Prostate cancer
Is the Subject Area "Prostate cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Transcription factors
Is the Subject Area "Transcription factors" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
COX-2 inhibitors
Is the Subject Area "COX-2 inhibitors" applicable to this article?

Thanks for your feedback.
DU145 cells
Is the Subject Area "DU145 cells" applicable to this article?

Thanks for your feedback.
Androgens
Is the Subject Area "Androgens" applicable to this article?

Thanks for your feedback.